California Pharmacy and Compounding Center, Newport Beach, CA

Is California Pharmacy and Compounding Center registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “De-registered as an Outsourcing Facility”.

Does California Pharmacy and Compounding Center hold a California pharmacy license?

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. The Texas State Board of Pharmacy also lists nonresident license 26686 for CALIFORNIA PHARMACY & COMPOUNDING CENTER, NEWPORT BEACH, CA, status Revocation, as of Nov 15, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 5858 for California Pharmacy and Compounding Center, Newport Beach, CA, status Voluntary Surrender, as of Nov 15, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002125 for CALIFORNIA PHARMACY & COMPOUNDING CENTER, NEWPORT BEACH, CA, status INACTIVE (DOES NOT WISH TO RENEW), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0000916 for California Pharmacy and Compounding Center, Newport Beach, CA, status Expired, as of Nov 10, 2026.

Has California Pharmacy and Compounding Center had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Feb 24, 2020) and 1 FMD-145 letter (Feb 24, 2020) for California Pharmacy and Compounding Center. State board actions: record found. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses lists 3 actions: “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Jun 4, 2025, case AC 7187 on license PHY 57141, “Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for 5 years and is subject to the terms and conditions in the decision” dated Sep 9, 2016, case AC 4628 on license PHY 49828 and “Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for 5 years and is subject to the terms and conditions in the decision” dated Sep 9, 2016, case AC 4628 on license LSC 99542. The Colorado State Board of Pharmacy’s license dataset also lists “CLS Voluntary Surrender/Relinquishment” dated Feb 21, 2017, case 2016-4750 on nonresident license OSP 5858. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
California Pharmacy and Compounding Center
Location
Newport Beach, CA
Type as FDA labels it
503A
FDA’s note
De-registered as an Outsourcing Facility
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Feb 24, 2020
FDA Data Dashboard inspections
4 inspections: 2 OAI, 2 VAI; 5 published Form 483s
Form 483 text on this page
2 Form 483s, 8 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as California Pharmacy and Compounding Center, a 503A facility, with 2 dated actions.

Document
Feb 24, 2020State referral letterState Referral Letter Issued 02/24/2020Not linked by FDA
Feb 24, 2020FMD-145 letterFMD-145 Letter Issued 02/24/2020Not linked by FDA

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists California Pharmacy & Compounding Center, Newport Beach, CA (FEI number 3004600090), matched to this page by exact name, city and state. It lists 4 inspections: 2 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Dec 17, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30046000901074872
Aug 31, 2016Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3004600090986751
Oct 17, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3004600090900112
Aug 25, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3004600090893386

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 8 numbered observations in all, across 2 inspections ending Oct 17, 2014 to Aug 31, 2016. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 2, 2016 to Aug 31, 2016: 5 observations

Firm on the cover
California Pharmacy & Compounding Center, 4000 Birch St Ste 120, Newport Beach, CA
FEI number
3004600090
Establishment type on the cover
92660- 2258 5038 Outsourcing Facility
FDA district office on the cover
19701 Fairchild; Irvine, CA 92612;
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically,

1) Media fills conducted within the ISO 5 Laminar Flow Hoods are inadequate. For example: a) They do not simulate the worst case scenario in your process to include the longest production times or human interventions as required in the Work Instruction WI-101-003-003. Your media fill matrix identified that Bevacizumab PFS production has the filling process REDACTED (b)(4). The media fills completed on REDACTED (b)(4) and thus they did not meet your maximum filling time.

b) You did not include gram negative bacteria and your in house representative isolates in the growth promotion challenge. c) You used REDACTED (b)(4) instead of REDACTED (b)(4) for media fill of Lidocaine HCL/Phenylephrine HCL (P-F) 1%/1.5% Injection as required in the Media Fill Logged Formula Worksheet. I

d) You failed to include vials/syringes that were rejected for particulates or physical defects during the media fill incubation. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, there is no scientific rational to support your personnel monitoring program can provide adequate assurance for your aseptic processing of drug products. The personnel monitoring samples (i.e. around REDACTED (b)(4) were taken REDACTED (b)(4).

Observation 3

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically, the REDACTED (b)(4) certifications for ISO 7 and ISO 8 area conducted on REDACTED (b)(4) failed to include HEP A filter leak testing for the filters located in ISO 7 and ISO 8 room.

Observation 4

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically, you failed to follow the written SOP No. P-101-002-C, Process Controls- Sterile Operations. that requires bacteria endotoxin to be performed [(5) (4) I [ J There were no documents to indicate that the bacteria endotoxin test was conducted for the following drug products:

1) Vancomycin Ophthalmic (lntravitreal) I mg/0.1 mL Syringe. 2) Ceftazidime Intravitreal 2.25 mg/0.1 mL (PFS).

Observation 5

1) The labels of your outsourcing facility's drug products do not include information required by section 503B (a) (10) (A) and (B). Specifically, the following information is not found on some of your drug product labels:

• The national drug code (NDC) number is not on your drug product labels. Labels for

the following drug products do not contain an NDC number:

o 0 o o 0

Dexamethasone SOD PHOS 16mglml (PF) Sol; Lidocaine 1% Phenylephrine 1.5% P-F 1ml SDV Bevacizumab/Dexamethasone 1.25mgllmg/0/1ml Injection; Vancomycin PF 1mg/0.1ml (SDV) Sol; Progesterone 100mg Canola Oil Cap

• The statements, "This is a compounded drug," "Not for resale," and "Office use only".

Examples of drug products that do not contain this information:

o o o

Alteplase 10mcg/0.1ml PF; Lidocaine 1% Phenylephrine 1.5% P-F 1ml SDV; Vancomycin 1mg/0.1ml Inj in NaCl 0.9%

• The lot or batch number is not on the product label for Testosterone PLO 4mg/ml Gel and Progesterone 100mg Canola Oil Cap.

The statement, "Office use only" is not on the product label for Cefuroxime

1mg/0.1ml in 0.9% NaCI Oph Injection 1ml vial. ...

Read the full 483 (PDF on fda.gov)

Inspection Oct 14, 2014 to Oct 17, 2014: 3 observations

Firm on the cover
California Pharmacy & Compounding Center, TRE AOORESS 4000 Birch St Ste 120
FEI number
3004600090
Establishment type on the cover
OUTSOURCING FACILITY Ne w ort Beach, CA 92660-2258
FDA district office on the cover
Not read
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

There is a failure to thorough ly review any unexplained discrepancy and the failure ofa batch or any of its components to

meet any of its specifications whether or not the batch hac; been already distributed.

Specifically,

Thorough investigatio ns were not conducted fo r complaints received by yo ur firm. For example:

A.

One patient adverse drug event (ADE) complaint was received by your firm fr om a Physician s of fice on 9/4/2014 for repackaged Avastin syringes. Doc umentation states that patient received Av astin in jection 1.2 5mg/0.05ml with lot REDACTED (b)(4) on 8/26/2014 but developed endophtalmitis associated with Avastin injection. No documentation could be provided that the compounding records were reviewed or that other related lots prepared during this time period were investigated.

On 5/16/2014, t hree p atient adverse drug events complaints, wi th AD E lo g #: ADE-1, ADE-2, and ADE 3 were rece ived due to p ati ent s use o f Be vacizumab (Avas tin) 1.25m g/0.05ml lot REDACTED (b)(6). According to the ADE reports, Bevacizumab (Avastin) 1.25mg/0.05ml with lot REDACTED (b)(6) was implicated in endophtalmitis; necessitating surgery to restore patients; vision. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Written records of investigations into the failure of a batch or any of its components to meet specifications do not include the conclusions and follow-up .

Specifically,

Microbial growths were observed in the following areas or during personnel monitoring:

Employee ' s left glove growth on 10/ 17114 (l cfu)

Employee's sterile face shield growth on 1 0/01/14 (3+cfu)

Employee's sterile gown growth on I 0/01114 (3 cfu)

Employee's sterile face shield growth on 10/02114 (result: "fail"- no cfu count was recorded)

Employee's sterile face shield growth on 10/07/14 (2 cfu)

Employee's sterile gown growth on 10/07/14 (1 cfu)

Employee ' s sterile gown growth on 1 0/09114 (2 cfu)

There were no investigation reports completed for the positive test results. You did not conduct any

microbial identification to understand the normal flora of cleanroom surfaces, personnel, and

environment.

Additionally, root cause corrective actions or preventive actions were not implemented, which is a

deviation from your firm's written procedure # A WI 4.30 Rev A titled "Area Work Instruction (A WI):

Gloved Fingertip Sampling Procedure," effective date 10/ 8/14, page 5, section 5.4.3 which states as ...

Read the full 483 (PDF on fda.gov)

Observation 3

Strict control is not exercised over labeling issued for use in drug product labeling operations.

Specifically,

Your firm lacks adequate controls for printing labels, issuing labels, examining issued labels, and reconciliation of used labels to prevent mix -ups.

For example,

A.

Your firm does not maintain a written and approved procedure describing the steps and practise

of label printing, issuance, examination, and reconciliation of the labels for your sterile and non­ sterile compounded drug products.

B. The results of the examination of labeled products were not documented in the batch production or control records. Specifically, there is no documentation of the review of each unit by the pharmacist of finished product after compounding prior to release and distribution. The review of labeled syringes prior to distribution for Bevacizumab (Avastin) lots B 101414A, B 101314, B100714, Bl01214, and B100114 was not documented.

C. Drug product labels are not stored under secure and access-restricted locations to avoid mix-ups. ...

Read the full 483 (PDF on fda.gov)

Linked 483s whose text is not shown

State board of pharmacy records

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.

Board actions

As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).

LicenseType as the board gives itName on the board recordLocationStatusPrior disciplinary orders (file flag)
26686Non Resident Sterile CompoundingCALIFORNIA PHARMACY & COMPOUNDING CENTERNEWPORT BEACH, CARevocationYes

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 5858OSPCalifornia Pharmacy and Compounding CenterNewport Beach, CAVoluntary Surrender

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002125NONRESIDENT PHARMACYCALIFORNIA PHARMACY & COMPOUNDING CENTERNEWPORT BEACH, CAINACTIVE (DOES NOT WISH TO RENEW)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0000916Non Resident PharmacyCalifornia Pharmacy and Compounding CenterNewport Beach, CAExpired

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.